Where is Evolva headquartered?

Evolva is located in Reinach, basel-country.

Who invested in Evolva?

Evolva has 13 investors including Geekdom Fund And Geekdom Fund.

When was the last funding round for Evolva?

Evolva closed its lastf unding roundon Jul 19, 2017 from a Convertible Note round.

Company Information
Company Timeline (Coming Soon)

evolva.com

Evolva

Evolva is a Switzerland-based biotechnology company that develops and commercializes products such as nature-based ingredients and flavors for the pharmaceutical industry.

Business Model:

Revenue: $10.8M

Employees: 51-200

Geographic Data

Address: Duggingerstrasse 23

City: Reinach

State: basel-country

Zip: CH-4153

Country: CH

Financial Info

Stage:

post ipo equity

Raised Last:

$7M

Raised Total:

$121M

Social

Twitter

Crunchbase

Metrics

0Website Global Rank

0Website Monthly Traffic

Twitter Followers

Description

Evolva is a Switzerland-based biotechnology company that develops and commercializes products such as nature-based ingredients and flavors for the pharmaceutical industry.

Contact Phone:

Contact Email:

IPO Details

Evolva went public on 12/1/2009 on the SIX Swiss Exchange

Listed Exchange:
SIX Swiss Exchange

IPO Date:
12/1/2009

Ticker Symbol:
EVE

Live

Opened: -/share

EBITDA	-
Total Cash	-
Total Debt	-
Total Revenue	-
Total Profit (Gross)	-
PE Ratio	-

Investments

Announced Date	Company	Transaction	Money Raised

Funding Rounds

Announced Date	Transaction	Number of Investors	Money Raised	Lead Investors
10/2022	Grant	1	$540k	Centers for Disease Control and Prevention Centers for Disease Control and Prevention
12/2009	Post-IPO Equity	9	$27.5M	Swisscom Ventures Novartis Venture Fund Aravis Ventures Wellington Partners Auriga Partners VINCI CAPITAL Entrepreneurs Fund Dansk Innovation BioMedPartners Swisscom Ventures Novartis Venture Fund Aravis Ventures Wellington Partners Auriga Partners VINCI CAPITAL Entrepreneurs Fund Dansk Innovation
12/2020	Post-IPO Equity	1	$13.5M	Nice &a; Green SA Nice &a; Green SA Nice &a; Green SA Nice &a; Green SA
10/2009	Series B	8	$27.8M	Aravis Ventures Astellas Venture Management Auriga Partners BioMedPartners Dansk Innovation Novartis Venture Fund VINCI CAPITAL Wellington Partners Aravis Ventures
3/2005	Series A	4	$2.6M	Yamanouchi Venture Capital Novartis Venture Fund Dansk Innovation APIDC Venture Capital
8/2004	Series A	4	$14.8M	Aravis Ventures Yamanouchi Venture Capital Novartis Venture Fund Dansk Innovation Aravis Ventures
12/2006	Series A	5	$10.3M	Yamanouchi Venture Capital Novartis Venture Fund Dansk Innovation Aravis Ventures APIDC Venture Capital
12/2021	Post-IPO Debt	1	$13.1M	Nice &a; Green SA Nice &a; Green SA Nice &a; Green SA Nice &a; Green SA
10/2022	Grant		$540k
11/2017	Post-IPO Equity		$86.1M
5/2022	Private Placement		$6.5M
5/2021	Post-IPO Debt		$22.2M	Nice & Green
12/2020	Post-IPO Debt		$13.3M	Nice & Green
1/2008	Grant		$5M
5/2022	Post-IPO Equity		$6.5M

Acquisitions

Announced Date	Name	Price
11/2014	Allylix
8/2014	Prosarix
11/2012	Fluxome
7/2011	Abunda Nutrition

Employee Demographics

Employee Departments

Employee States

Similar Companies

Uniview Singapore VEID	Revenue: 0 - 100000 Employees: Industry: Software	Details
Konkuk University Medical Center	Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education	Details
Daemon Technologies	Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain	Details
Ace International Trade	Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial	Details
An Hòa Communications	Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising	Details